HBOC-201 Vasoactivity in a Phase III Clinical Trial in Orthopedic Surgery Subjects-Extrapolation of Potential Risk for Acute Trauma Trials.
BACKGROUND:: Vasoactivity has hampered progress of hemoglobin-based oxygen carriers (HBOCs) due to concern for adverse blood pressure responses and secondary complications. A recent formulation, highly polymerized HBOC-201 (Biopure, Cambridge, MA), has been found to be less vasoactive than prior les...
| Publicado en: | Journal of Trauma Vol. 66; no. 2; pp. 365 - 377 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Feb2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |